- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
U.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV
Data shows PREZISTA® is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy through delivery
U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets Intended to Treat Soil-Transmitted Helminthiasis
Johnson & Johnson shows ongoing commitment to London Declaration on NTDs through advancement of new chewable tablet
SIMPONI® Receives European Commission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis
Health Authority Approval Marks Sixth Indication for SIMPONI in Europe
Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD)
- In current clinical practice, there are no FDA-approved treatments for this life-threatening condition - FDA designation suggests potential use of ibrutinib beyond hematologic malignancies - The FDA also granted ibrutinib orphan drug designation for cGVHD
Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease QuickFire Challenge
Largest QuickFire competition to date will award up to $500,000 in a research grant and entrance to Johnson & Johnson Innovation, JLABS, to promising transformational healthcare solution Challenge launched at 2016 BIO International Convention during the Bionic Innovation Forum
Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors
Other Presentations at American Diabetes Association Scientific Sessions® Show INVOKANA® Therapy also is Associated with Achieving Blood Glucose and Blood Pressure Treatment Goals
New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management
Combination of Canagliflozin and Phentermine Demonstrates Improvements in Weight Management in Overweight or Obese Patients without T2DM